Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (SABES?)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Fred Hutchinson Cancer Research Center
Sponsor:
Collaborators:
Asociación Civil Impacta Salud y Educación, Peru
NGO Via Libre
Epicentro, Barranco District, Peru
Information provided by (Responsible Party):
Duerr, Ann C, Fred Hutchinson Cancer Research Center
ClinicalTrials.gov Identifier:
NCT01815580
First received: March 15, 2013
Last updated: September 3, 2014
Last verified: September 2014

March 15, 2013
September 3, 2014
July 2013
June 2016   (final data collection date for primary outcome measure)
HIV viral load [ Time Frame: four years ] [ Designated as safety issue: No ]
To quantify HIV viral load in plasma, semen and rectal secretions in individuals with early HIV infection in immediate versus deferred treatment groups.
Same as current
Complete list of historical versions of study NCT01815580 on ClinicalTrials.gov Archive Site
  • Risk factors for acute/recent HIV infection [ Time Frame: four years ] [ Designated as safety issue: No ]
    To identify risk factors associated with incident HIV-1 infection among MSM and transgender women in Peru.
  • Linkage to care [ Time Frame: four years ] [ Designated as safety issue: No ]
    To determine the proportion of individuals with evidence of acute infection (HIV-1 RNA-positive) who are successfully contacted for confirmatory HIV testing and are then linked to care.
  • Retention in care [ Time Frame: four years ] [ Designated as safety issue: No ]
    To determine the proportion of men retained in care, including adherence to ART and study procedures, among individuals with early HIV-1 infection receiving immediate and deferred ART.
Same as current
Not Provided
Not Provided
 
HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women
HIV Testing and Treatment to Prevent Onward HIV Transmission Among MSM and Transgender Women in Lima, Peru

This study will recruit men and transgender women with acute or recent HIV infection. It wil look at how HIV medicines (ART) when given very early after HIV infection affect the amount of HIV in the blood, semen and rectal secretions. In addition, Investigators will be using modeling studies to look at whether or not this kind of HIV treatment can decrease the risk that a man will infect a person he has sex with and to find out how failure to take medications will impact spreading the virus to other people.

In this study, one group will be randomized (like a coin toss) to start ART immediately (just at the time of the enrollment visit) and the other group will wait until week 24 of the study to start ART. Both groups will be followed for a total of 48 weeks and will continue to receive ART from local sources after the study is over.

This is three-step study. Step 1 will screen men who have sex with men (MSM) and transgender women who are unaware of their HIV status and 1) report high risk behaviors for acquiring HIV-1 infection or 2) who have symptoms of acute retroviral syndrome or 3) who have a sexual partner with newly-diagnosed acute or recent HIV infection. HIV testing will be conducted for several thousand MSM and transgender women from study opening until July 2015. In Step 2, high risk HIV-1 uninfected MSM and transgender women with high risk for acquiring HIV will be tested at regular intervals for incident HIV-1 (using tests for HIV p24 and/or HIV RNA). (During this period, men will receive standard HIV prevention interventions.) In Step 3, individuals with acute or recent HIV-1 infection will be enrolled in a 48-week randomized, open-label study of the effects of immediate vs. deferred ART on the decay dynamics of HIV viral load in plasma, semen and rectal secretions. (ART will be provided prior to 24 weeks for any participant in the deferred ART arm who meets initiation criteria.) All participants will be followed for 48 weeks after which they will continue ART from other sources.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
HIV
Drug: Atripla
Antiretroviral therapy
Other Name: (alternate: Truvada + 3rd ARV)
  • Active Comparator: Immediate ART (Atripla)
    Daily Atripla will be provided to these patients for the duration of the study beginning at enrollment.
    Intervention: Drug: Atripla
  • Placebo Comparator: Deferred ART (Atripla)
    Daily Atripla will be provided to these patients for the duration of the study beginning at 24 weeks.
    Intervention: Drug: Atripla
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
December 2016
June 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult men who have sex with men, and transgender women
  • Unaware of HIV status at enrollment in follow-up cohort
  • High risk for HIV infection
  • Willing to test for HIV
  • No prior ART, including prior administration of pre- and post-exposure prophylaxis in the last 30 days
  • Willing to provide informed consent

Exclusion Criteria:

  • Prior receipt of investigational anti-HIV vaccine
  • Ongoing therapy with any of the following:

    1. Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed
    2. Systemic chemotherapeutic agents
    3. Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine
    4. Immunomodulatory treatments including Interleukin-2
    5. Investigational agents
  • Known allergy/sensitivity or any hypersensitivity to components of study drugs (ART) or their formulations
  • Active drug or alcohol use or dependence that would interfere with adherence to study requirements
  • Serious medical or psychiatric illness that would interfere with the ability to adhere to study requirements
  • Chronic or acute hepatitis B infection
  • Use of female hormonal products based on estrogen or derivatives
Male
18 Years and older
Yes
Peru
 
NCT01815580
TNT-Peru
No
Duerr, Ann C, Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
  • Asociación Civil Impacta Salud y Educación, Peru
  • NGO Via Libre
  • Epicentro, Barranco District, Peru
Principal Investigator: Ann Duerr, M.D. Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP